Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance and optimistic guidance, particularly with increased revenue guidance and global expansion. The management's confidence in product launches and pipeline development, alongside positive reception from payers and no significant barriers, suggest a positive outlook. Although some uncertainties exist, such as CMS reimbursement changes, the overall sentiment remains positive with growth prospects in multiple areas.
Key Financial Performance
TTR franchise revenues $724 million, 135% year-over-year growth. Growth largely attributable to the AMVUTTRA CM launch in the U.S., achieving total TTR revenues of $543 million, representing 194% year-over-year growth. The broader balance uptake in the second full quarter of launch drove an approximate doubling of TTR cardiomyopathy revenue compared to the prior quarter.
Total net product revenues $851 million, up 103% year-over-year. Growth driven by strong performance of the TTR franchise and the AMVUTTRA ATTR-CM launch.
Rare disease portfolio sales $127 million, up 14% versus Q3 2024. Growth driven largely by ongoing patient demand.
Collaboration revenue $352 million, representing a $294 million increase compared with last year. Increase primarily due to revenue recognized under collaboration and license agreement with Roche, including $300 million of milestone revenue.
Royalty revenue $46 million, doubling compared with last year. Growth driven by higher LEQVIO sales as Novartis continues to grow the product globally.
Gross margin on product sales 77% for the quarter, compared with 80% in Q3 2024. Decrease driven by increased royalties on AMVUTTRA as higher revenues resulted in an increase in the royalty rate.
Non-GAAP R&D expenses $310 million, increased 23% compared to last year. Increase driven by costs associated with the initiation of multiple Phase III clinical studies.
Non-GAAP SG&A expenses $263 million, increased 35% compared to last year. Increase driven by increased headcount and investments in support of the AMVUTTRA ATTR cardiomyopathy launch in the U.S.
Non-GAAP operating income $476 million, representing a $507 million increase compared with last year. Growth driven by strong top line results in product sales and revenue from collaborations.
Cash, cash equivalents, and marketable securities $2.7 billion, similar to the end of 2024. Cash impacted by refinancing activities, including issuance of new convertible notes and repurchase of convertible senior notes.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AMVUTTRA cardiomyopathy launch: Delivered strong quarterly performance with TTR franchise revenues of $724 million, a 135% year-over-year growth. U.S. TTR revenues reached $543 million, a 194% year-over-year growth.
Pipeline advancements: Initiated ZENITH Phase III cardiovascular outcomes trial for zilebesiran in hypertension and TRITON-PN study for nucresiran in hATTR-PN. Progress in bleeding and neurologic disorders.
Rare disease portfolio: Achieved $127 million in sales, up 14% year-over-year, driven by ongoing patient demand.
U.S. market growth: U.S. TTR franchise grew 42% quarter-over-quarter and 194% year-over-year, driven by AMVUTTRA ATTR-CM label expansion.
International market expansion: Revenues grew 13% quarter-over-quarter and 46% year-over-year. Early progress in Japan and Germany for AMVUTTRA ATTR-CM launch.
Financial performance: Achieved $851 million in total net product revenues, up 103% year-over-year. Increased 2025 revenue guidance to $2.95 billion-$3.05 billion.
Operational efficiency: Completed health system setup for AMVUTTRA in the U.S., ensuring 90% of patients can access treatment within 10 miles.
Strategic focus on TTR leadership: Dedicated to establishing long-term leadership in TTR with strong U.S. and international growth.
Innovation-driven growth: Focused on multibillion-dollar opportunities within the pipeline, including RNAi therapeutics and new indications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces potential challenges in international markets, such as Germany, where final reimbursement decisions are still pending, which could delay the broader adoption of AMVUTTRA.
Regulatory Hurdles: The international AMVUTTRA ATTR-CM launches are contingent on the completion of local pricing and reimbursement reviews, which could delay market entry in key regions.
Competitive Pressures: The rare disease portfolio faces new competition, which could impact the growth trajectory of the hATTR polyneuropathy legacy business.
Economic Uncertainties: The company’s gross margin on product sales is expected to decrease due to increased royalties on AMVUTTRA, which could impact profitability.
Strategic Execution Risks: The company is heavily reliant on the success of AMVUTTRA and its TTR franchise for growth, which poses a risk if market adoption or competitive dynamics shift unfavorably.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Alnylam has increased its total net product revenue guidance for 2025 from the range of $2.65 billion to $2.8 billion to a revised range of $2.95 billion to $3.05 billion, representing a $275 million or 10% increase at the midpoint. This reflects confidence in the AMVUTTRA ATTR-CM launch and other commercial products.
TTR Franchise Revenue: The guidance for the TTR franchise has been increased from $2.175 billion to $2.275 billion to a revised range of $2.475 billion to $2.525 billion, representing a 12% increase at the midpoint.
Ex-U.S. Launches: International AMVUTTRA ATTR-CM launches are anticipated across 2026, following the completion of local pricing and reimbursement reviews, which will extend global reach and contribute to launch momentum.
Pipeline Developments: The ZENITH Phase III cardiovascular outcomes trial of zilebesiran in hypertension has been initiated, with a potential launch around 2030. The TRITON-PN study of nucresiran in hATTR-PN will be initiated shortly, with top-line results expected in 2028. A Phase II trial of ALN-6400 in hereditary hemorrhagic telangiectasia (HHT) is underway, and a Phase I trial of ALN-5288 for Alzheimer's disease has been initiated.
AMVUTTRA ATTR-CM U.S. Launch: The U.S. launch of AMVUTTRA ATTR-CM continues to show strong momentum, with patient demand doubling quarter-over-quarter. The health system setup is complete, and payer coverage is broad, with nearly all patients having access to AMVUTTRA as a first-line treatment option.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you just speak with regard to AMVUTTRA, how the momentum is going in the first-line versus switchers population and maybe talk about any combo use? And any clarity here on ex U.S. pricing would be helpful as well.
A:Management highlighted strong momentum for AMVUTTRA, with doubled patient demand in cardiomyopathy in the U.S. They noted broad adoption across academic and community settings and growth in first-line share while maintaining leadership in second-line. Ex U.S. pricing is still under negotiation, with a compelling profile in Japan and early-stage discussions in Germany. Combination use is minimal but expected to grow as tafamidis goes generic.
Q:What gives you confidence that you're going to continue to see an acceleration in patient adds next year and going into the end of this year? And any color on patient switches from stabilizers would really be helpful?
A:Management expressed confidence in continued growth, citing a strong launch and raised guidance twice. They clarified that ONPATTRO's decline was due to a one-time Medicaid adjustment in the prior quarter. They emphasized balanced uptake across first-line and second-line patients and maintained leadership in patients progressing on stabilizers.
Q:Can you just talk about what led to the decision to pursue the MAPT program and your confidence in the target? Does this say anything about your ALN-APP program in Alzheimer's as well?
A:Management is excited about the MAPT program, emphasizing RNA interference therapeutics' potential in neurodegenerative diseases. They highlighted tau as a genetically validated target in Alzheimer's and tauopathies. They view this as part of a broader portfolio addressing severe neurodegenerative diseases, alongside the ALN-APP program.
Q:How are you getting feedback from payers? Is there going to be any risk of payers preferring a stabilizer to a silencer or ordering which of the products they might prefer?
A:Management reported no payer headwinds and noted that payers appreciate the value of AMVUTTRA. They observed no significant barriers like step edits or high co-pays and are negotiating policies for 2026, expecting dynamics similar to early launch.
Q:Can you comment more on the inventory demand number for third quarter and how to think about that for fourth quarter, along with gross to net? And can you walk us through your expectations for fourth quarter revenues in the EU and how to think about the ramp up there?
A:Inventory days on hand remained constant, with growth driven by ramping demand. Gross to net increased due to ONPATTRO's prior Medicaid adjustment. Ex U.S. contributions will remain modest in Q4, with limited impact from Germany and Japan. Broader growth is expected in mid-to-late 2026.
Q:Can you elaborate on the approach you took to updating the TTR franchise guidance this time around in light of the fact that, as you said, we're still just 2 quarters into the cardiomyopathy launch?
A:Guidance was updated based on Q4 predictions, estimating $850M-$900M in global TTR revenue. Management emphasized improving forecasting ability as more data becomes available, with the midpoint of the range being the most likely outcome.
Q:CMS is proposing to cut reimbursement for PYP scintigraphy by 57%. What was your reaction to that news? Do you think CMS will also look at the therapeutic side of the equation?
A:Management is monitoring the reimbursement changes but has not observed concerns from health systems. They anticipate more diagnosis and scanning and will adapt as policies become clearer. No specific comments were made about potential impacts on therapeutics.
Q:Can you confirm that the price for AMVUTTRA will decline at mid-single digits year-over-year in the U.S.? Once you launch ATTR cardiomyopathy in Europe, how should we think about price change in Europe? And what is the ratio between first-line versus second-line use in the U.S.?
A:Management confirmed a gradual decline in net price over time in the U.S. European pricing negotiations are ongoing, with broader updates expected in 2026. First-line use is growing, with a balanced uptake between first- and second-line patients.
Q:What degree of commercial investment is needed in Europe to expand beyond the PN indication? How does center type impact first-line use?
A:Management noted limited field activity is required in Europe due to treatment being concentrated in centers of excellence. Cardiomyopathy patients are also treated in these centers, minimizing the need for significant expansion. Center type and patient characteristics influence first-line use.
Q:Should we model a similar jump up for AMVUTTRA as seen with tafamidis trends from Q4 to Q1? Is this due to IRA Part D modifications or normal seasonality?
A:Management observed accelerating category growth in ATTR-CM, driven by underdiagnosis and undertreatment. They emphasized AMVUTTRA's differentiation and ongoing investments in real-world evidence and data generation, positioning it as a market leader.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the potential impact of CMS reimbursement cuts on therapeutics, stating they are monitoring the situation but providing no specific insights. Additionally, they did not provide detailed breakdowns of first-line versus second-line use or European pricing expectations, citing ongoing negotiations and early-stage dynamics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMVUTTRA ATTR
CM launch
III outcome
III trial
Phase II
Phase III
TRITON PN
TTR category
TTR revenue
Today
adoption
arm
bleeding disorder
blood pressure
clot
control blood
effect
event
ex
fibrinolysis
hATTR PN
health system
hypertension risk
increase deduction
individual
loss function
momentum AMVUTTRA
momentum TTR
month endpoint
nucresiran
outcome trial
pillar
placebo
system setup
trajectory
trial patient
vutrisiran
year
zilebesiran
ALNY Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call shows strong financial performance with a significant increase in operating income and cash reserves. The company has a strategic plan with robust revenue growth projections and a focus on expanding its product pipeline. The Q&A session reveals confidence in AMVUTTRA's market positioning and growth potential, despite competitive threats. While there are increased expenses, they are tied to growth initiatives. The sentiment is positive, supported by strong financial metrics and optimistic guidance, suggesting a likely stock price increase in the short term.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
ALNY Slides
ALNY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
